Talk:Insulin aspart

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Insulin aspart.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Name

The insulin named in the article as "NovoLog Mix 70/30" is actually marketed, in the UK at least, as NovoMix 30. I suspect that this is a case of regional variation of brand names (e.g. paracetamol/acetaminophen). — Korax1214 (talk) 18:07, 24 April 2015 (UTC)[reply]

Suspicious addition

Call me paranoid, but someone has added a statement that strikes me as something a staffmember at a massive lobbyist organization bankrolled by the US health insurance industry would add. It's basically an argument to stop prescribing modern (expensive) insulin. It reads "As of 2018 there is a lack of compelling evidence to conclude superiority of insulin aspart over human insulin in type 2 DM.[9] It is thus unclear why the shifting of people from human insulin to insulin aspart has occurred.[10] In type 1 DM it appears to result in slightly better blood sugar control.[11]". It is cited, but has only one source out of the millions of papers published annually, some also bankrolled by special interests. It screamed "agenda" immediately when I read it. It doesn't sit well with me. Habanero-tan (talk) 21:21, 31 July 2019 (UTC)[reply]